Zacks Investment Research upgraded shares of Ablynx Nv (OTCMKTS:ABLYF) from a hold rating to a buy rating in a report published on Wednesday morning. Zacks Investment Research currently has $25.00 target price on the stock.

According to Zacks, “Ablynx NV is a biopharmaceutical company which engaged in the development of Nanobodies (R) proprietary therapeutic proteins based on single-domain antibody fragments. The company also discovers and develops therapeutic for inflammation, haematology, immuno-oncology, oncology and respiratory disease. Ablynx NV is headquartered in Ghent, Belgium. “

Separately, Bank of America Corporation assumed coverage on Ablynx Nv in a research note on Friday, November 10th. They set a buy rating and a $26.00 price target for the company.

Shares of Ablynx Nv (OTCMKTS:ABLYF) opened at $22.53 on Wednesday. Ablynx Nv has a 1-year low of $9.75 and a 1-year high of $50.00.

ILLEGAL ACTIVITY WARNING: This piece was reported by Watch List News and is owned by of Watch List News. If you are reading this piece on another publication, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be viewed at https://www.watchlistnews.com/ablynx-nv-ablyf-upgraded-at-zacks-investment-research/1725055.html.

Ablynx Nv Company Profile

Ablynx NV, a biopharmaceutical company, develops Nanobodies that is a proprietary therapeutic protein based on single-domain antibody fragments for the treatment of various diseases. The company develops products in various therapeutic areas, such as inflammation, hematology, immuno-oncology, oncology, and respiratory diseases.

Get a free copy of the Zacks research report on Ablynx Nv (ABLYF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Ablynx Nv Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ablynx Nv and related companies with Analyst Ratings Network's FREE daily email newsletter.